20 articles
A comprehensive review reveals methylene blue's expanding role from toxicology emergencies to perioperative care, neurology, and oncology.
Current labeling urges nursing mothers to pause breastfeeding for 8 days after methylene blue, but the underlying evidence is thin.
FDA-approved methylene blue reduced delirium-like behavior in surgical mice by suppressing neuroinflammation and repairing the blood-brain barrier.
A meta-analysis of 15 studies finds methylene blue therapy significantly reduces mortality in ICU septic shock patients, with hemodynamic benefits.
A 2025 review examines how methylene blue's nitric oxide inhibition can restore vascular tone in septic and vasoplegic shock patients.
A primate study shows methylene blue treats fatal cerebral malaria and uncovers neutrophil-linked genes as diagnostic biomarkers.
A 566-patient multicenter RCT launching across China to determine if early methylene blue reduces 28-day mortality in high-dose vasopressor-dependent septic shock.
A 200-patient study finds early methylene blue use in post-bypass vasoplegic shock halves ICU stays and reduces kidney failure rates.
A case report from Surrey and Sussex NHS Trust highlights risks of methylene blue extravasation into hand and forearm during parathyroid surgery.
A comprehensive review reveals how advanced oxidation processes can efficiently degrade methylene blue, a persistent textile pollutant threatening human health.
Adding methylene blue to ropivacaine in a serratus anterior plane block significantly prolongs pain relief up to 72 hours post-op.
New research shows blue light triggers harmful changes in retinal cells by disrupting mitochondrial function, offering targets for AMD prevention.
MethylCog, a 29-CpG blood test, indexes general cognitive ability and improves mild cognitive impairment detection beyond age and sex alone.
A 4-week-old infant developed severe methemoglobinemia after EMLA cream was applied for circumcision, highlighting hidden dangers of topical anesthetics.
A Cochrane meta-analysis of 17 RCTs finds blue light TURBT reduces bladder cancer recurrence and progression, especially in intermediate- and high-risk patients.
Morning blue light exposure stabilized attention during cognitive tasks, reducing moment-to-moment mental variability in young adults.
A 303-tumor study shows DNA methylation arrays can classify neuroblastoma into prognostically meaningful subgroups, potentially replacing multiple genomic tests.
Cyanidin-3-O-glucoside, a natural anthocyanin, reduces immunosuppressive Tregs and slows multiple myeloma growth in mice and cell studies.
Delphinidin, a natural anthocyanin, prevented microglial senescence via AMPK/SIRT1 signaling, reducing amyloid plaques and restoring cognition in AD mice.
A comprehensive 2025 review details how gene therapy, transplant advances, and newborn screening are reshaping outcomes for this fatal brain disease.
